What were the results of the CORONA and GISSI studies?
The CORONA and GISSI studies showed that rosuvastatin reduced the risk of total hospitalizations, hospitalizations for a cardiovascular cause, and hospitalizations for worsening HF in CORONA. A subsequent analysis accounting for repeat HF hospitalizations showed a significant reduction in HF hospitalizations. Post hoc analyses from CORONA showed that patients randomized to rosuvastatin with less advanced HF with reduced ejection fraction had a significant reduction in the primary outcome, but no benefit was seen among patients with more advanced HF. A subsequent analysis that pooled data from both these trials and accounted for competing causes of death showed a significant 19% reduction in the risk of MI with rosuvastatin in patients with ischemic HF, although the ARR was small.